6.58
4.28%
0.27
전일 마감가:
$6.31
열려 있는:
$6.38
하루 거래량:
1.55M
Relative Volume:
1.58
시가총액:
$773.69M
수익:
-
순이익/손실:
$-174.61M
주가수익비율:
-3.3401
EPS:
-1.97
순현금흐름:
$-165.54M
1주 성능:
+4.78%
1개월 성능:
-17.13%
6개월 성능:
-21.20%
1년 성능:
-40.40%
89 Bio Inc Stock (ETNB) Company Profile
명칭
89 Bio Inc
전화
(415) 432-9270
주소
142 SANSOME STREET, SAN FRANCISCO, CA
ETNB을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
6.58 | 773.69M | 0 | -174.61M | -165.54M | -1.97 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-04-22 | 재개 | BofA Securities | Buy |
2024-01-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2023-08-28 | 개시 | UBS | Buy |
2023-06-13 | 개시 | Evercore ISI | Outperform |
2022-05-12 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2021-12-20 | 개시 | H.C. Wainwright | Buy |
2021-10-26 | 재개 | Cantor Fitzgerald | Overweight |
2021-07-29 | 재개 | BTIG Research | Buy |
2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
2021-04-21 | 개시 | Cantor Fitzgerald | Overweight |
2020-10-19 | 개시 | Raymond James | Strong Buy |
2020-09-25 | 업그레이드 | BofA Securities | Neutral → Buy |
2020-07-31 | 개시 | Piper Sandler | Overweight |
2020-07-23 | 개시 | BTIG Research | Buy |
2020-07-07 | 개시 | Chardan Capital Markets | Buy |
2019-12-09 | 개시 | BofA/Merrill | Neutral |
2019-12-09 | 개시 | Oppenheimer | Outperform |
2019-12-09 | 개시 | RBC Capital Mkts | Outperform |
2019-12-09 | 개시 | SVB Leerink | Outperform |
모두보기
89 Bio Inc 주식(ETNB)의 최신 뉴스
89bio shares maintain Buy rating as analyst cites confidence in pegozafermin trial outcomes - MSN
HC Wainwright Reiterates Buy Rating for 89bio (NASDAQ:ETNB) - MarketBeat
Weiss Ratings Reiterates Sell (D-) Rating for 89bio (NASDAQ:ETNB) - MarketBeat
Hennion & Walsh Asset Management Inc. Takes $739,000 Position in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio (NASDAQ: ETNB) Provides Corporate Update and Business Outlook for 2025SAN FRANCISCO, January 13, 2025 (GLOBE NEWSWIRE) – 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company specializing in innovative therapies for l - Defense World
Weiss Ratings Reiterates “Sell (D-)” Rating for 89bio (NASDAQ:ETNB) - Defense World
89bio, Inc. (NASDAQ:ETNB) Short Interest Up 12.2% in December - MarketBeat
89bio (NASDAQ:ETNB) Hits New 12-Month Low After Insider Selling - Defense World
89bio, Inc. (NASDAQ:ETNB) Insider Sells $71,149.87 in Stock - MarketBeat
89bio's chief technical operations officer sells $71,149 in stock - MSN
89bio's chief technical operations officer sells $71,149 in stock By Investing.com - Investing.com South Africa
89bio (NASDAQ:ETNB) Stock Price Down 4%Time to Sell? - MarketBeat
89bio (NASDAQ:ETNB) Reaches New 12-Month LowTime to Sell? - MarketBeat
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward (NASDAQ:ETNB) - Seeking Alpha
89bio Provides Business Update and Outlook for 2025 - The Manila Times
89bio Completes Phase 3 Trial Enrollment, Fortifies Position with $440M Cash Reserve - StockTitan
89bio (NASDAQ:ETNB) Sets New 1-Year Low – Should You Sell? - Defense World
89bio, Inc. (NASDAQ:ETNB) Shares Acquired by Barclays PLC - MarketBeat
Barclays PLC Acquires 149,479 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
Certain Warrant of 89bio, Inc. are subject to a Lock-Up Agreement Ending on 12-JAN-2025. - Marketscreener.com
89bio (NASDAQ:ETNB) Hits New 52-Week LowHere's Why - MarketBeat
89bio stock hits 52-week low at $6.42 amid market challenges By Investing.com - Investing.com South Africa
89bio stock hits 52-week low at $6.42 amid market challenges - Investing.com Australia
89bio (NASDAQ:ETNB) Stock Price Down 8.2%Here's What Happened - MarketBeat
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Madrigal Pharmac, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking - The Globe and Mail
Biotech manufacturer plans to cut 120 jobs in Durham - WRAL News
Brokerages Set 89bio, Inc. (NASDAQ:ETNB) PT at $30.33 - Defense World
89bio's SWOT analysis: pegozafermin potential drives stock outlook By Investing.com - Investing.com Australia
89bio (NASDAQ:ETNB) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
89bio’s SWOT analysis: pegozafermin potential drives stock outlook By Investing.com - Investing.com Nigeria
89bio's SWOT analysis: pegozafermin potential drives stock outlook - Investing.com India
89bio (NASDAQ:ETNB) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
89bio, Inc. (NASDAQ:ETNB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Head to Head Review: VectivBio (NASDAQ:VECT) versus Tourmaline Bio (NASDAQ:TRML) - Defense World
89bio (NASDAQ:ETNB) Stock Price Down 3.7%Should You Sell? - MarketBeat
Jane Street Group LLC Has $1.03 Million Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Jane Street Group LLC Has $1.03 Million Stock Holdings in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio, Inc. (NASDAQ:ETNB) Shares Purchased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Has $15.36 Million Stock Holdings in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
Barclays PLC Boosts Stock Holdings in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Barclays PLC Raises Stock Position in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio, Inc. (NASDAQ:ETNB) Holdings Reduced by Franklin Resources Inc. - MarketBeat
89bio Grants Retention RSUs to Key Officers - Defense World
State Street Corp Acquires 7,184 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio (NASDAQ:ETNB) Sets New 52-Week Low – Here’s Why - Defense World
89bio (NASDAQ:ETNB) Sets New 52-Week LowHere's Why - MarketBeat
89bio stock hits 52-week low at $6.96 amid market challenges - Investing.com Canada
89 Bio Inc (ETNB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):